News

Gene Predictis will benefit from CTI’s expertise

Gene Predictis has been accepted in the Swiss Commission for Technology and Innovation (CTI) start-up coaching program.
CTI promotes innovative development of young Swiss companies, providing professional expertise in business management and development.

Given this support, Gene Predictis does aim to strengthen its ability to address customers’ needs in the field of pharmacogenetics and develop new solutions to offer accessible genetic passports (CYPASS ™) that will allow physicians to individualise drug prescription.

This is a cardinal issue, given that adverse drug reactions (ADR) are involved in up to 7% of hospital emergency admissions in Switzerland and up to 18% in the US. Moreover, fatal ADR brings about 3% of the Swedish death rate, and it is the 4th most common cause of death in US hospital patients.

Predictive medicine inferred from genetics